> Research Use Only Disclaimer: Hexarelin is a research peptide not approved by the FDA for human use. All dosing information, protocols, and data presented in this article are sourced from peer-reviewed scientific literature and are provided strictly for educational and research purposes. This article does not constitute medical advice. Do not administer hexarelin or any research peptide to humans.
What Is Hexarelin?
Hexarelin (hexarelin acetate; also written Examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS) and the most potent member of the GHRP (growth hormone-releasing peptide) class. It was developed in the 1990s by Europeptides and studied clinically for growth hormone deficiency, cardiac protection, and muscle wasting — though it never received regulatory approval.
Its sequence — His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ — mimics the endogenous ghrelin signal but with higher receptor affinity and greater GH-releasing potency than any other synthetic GHRP.
Why Hexarelin Is Unique Among GHRPs
Most GHRPs (GHRP-2, GHRP-6, Ipamorelin) are relatively selective agonists at the growth hormone secretagogue receptor type 1a (GHSR-1a). Hexarelin is also a GHSR-1a agonist, but several features set it apart:
- •Highest GH release: Hexarelin produces the largest acute GH pulse of any synthetic GHRP tested in human and animal studies — roughly 2–3× the GH area under the curve (AUC) versus GHRP-2 at equivalent molar doses (Arvat et al., 1997)
- •Cardioprotective receptor activity: Hexarelin binds the CD36 scavenger receptor and cardiovascular GHSR-related receptors, producing direct cardioprotective effects independent of GH secretion (Mao et al., 2007)
- •Cortisol and prolactin co-release: Unlike Ipamorelin (which is highly selective), hexarelin stimulates cortisol and prolactin release in addition to GH — an important consideration in research design
- •Rapid desensitization: Hexarelin's potency is also its limitation in sustained research — pituitary GH response declines significantly with chronic daily dosing, typically within 2–4 weeks
These properties make hexarelin a valuable tool in cardiac research, GH physiology studies, and receptor pharmacology — while also requiring careful dosing protocols to manage desensitization.
---
Hexarelin Mechanism of Action: GHSR-1a and Beyond
Primary Pathway: GHSR-1a Agonism
Hexarelin binds with high affinity to GHSR-1a, the primary receptor for ghrelin, located in the hypothalamus and pituitary gland. This triggers:
1. Hypothalamic signaling: Hexarelin stimulates GHRH (growth hormone-releasing hormone) release from hypothalamic neurons
2. Pituitary amplification: At the pituitary, hexarelin directly stimulates somatotroph cells to release GH via calcium-dependent signaling
3. Synergistic release: The combined hypothalamic + direct pituitary action explains hexarelin's superior GH pulse amplitude compared to GHRPs that act primarily at one site
This dual-site action is also why hexarelin produces higher GH pulses than native GHRH alone, and why combining hexarelin with a GHRH analog (CJC-1295, Sermorelin) produces synergistic — not merely additive — GH release.
Secondary Pathway: CD36 and Cardiovascular GHSR Isoforms
Independent of GHSR-1a, hexarelin activates CD36 (scavenger receptor B2) and non-GHS cardiac receptors. Research has shown hexarelin:
- •Reduces infarct size in ischemia-reperfusion models (Broglio et al., 2003)
- •Improves ventricular function and cardiac output in heart failure models
- •Attenuates cardiomyocyte apoptosis post-ischemic injury
- •Acts through ERK1/2 and PI3K/Akt cardioprotective signaling cascades
This cardiac activity persists in hypophysectomized animals (those without a pituitary), confirming the mechanism is GH-independent and receptor-direct.
---
Hexarelin vs. Other GHRPs: Potency Comparison
| GHRP | GH Pulse Potency | Cortisol/Prolactin | Appetite Stimulation | Desensitization Risk |
|---|---|---|---|---|
| Hexarelin | ★★★★★ (Highest) | High | Moderate | High (rapid) |
| GHRP-2 | ★★★★☆ | Moderate | Low | Moderate |
| GHRP-6 | ★★★☆☆ | Moderate | High | Moderate |
| Ipamorelin | ★★☆☆☆ | None | None | Low |
| MK-677 (oral) | ★★★☆☆ | Low | High | Low |
Key Research Implication: Hexarelin's superior potency makes it the preferred GHRP when researchers need maximal acute GH stimulation. However, for sustained, low-interference GH research, Ipamorelin or GHRP-2 are often preferred due to their cleaner selectivity profiles.
---
Research Dosing Ranges: What the Literature Reports
Standard Research Dose Range
Published human pharmacokinetic and pharmacodynamic studies on hexarelin cluster around a narrow dose range:
- •Low dose (sensitivity testing): 0.5–1.0 mcg/kg body weight
- •Standard research dose: 1.0–2.0 mcg/kg body weight (most commonly used in published studies)
- •High dose (receptor saturation studies): 2.0–3.0 mcg/kg body weight
For a 75 kg (165 lb) research subject reference:
- •Low dose: ~37.5–75 mcg per injection
- •Standard dose: ~75–150 mcg per injection
- •High dose: ~150–225 mcg per injection
The most commonly cited dose in clinical studies is 1–2 mcg/kg, which for most adults equates to approximately 100–200 mcg per injection.
Dose-Response Relationship
A key finding from hexarelin research is that GH release follows a non-linear dose-response curve — meaning dose increases beyond ~2 mcg/kg produce diminishing additional GH release while substantially increasing side effect burden (cortisol, prolactin). This saturation effect is more pronounced in hexarelin than in other GHRPs, reinforcing the use of moderate rather than high doses in research protocols.
Frequency Protocols Observed in Research
Published protocols vary by research objective:
| Protocol Type | Frequency | Purpose in Research |
|---|---|---|
| Acute stimulation | Single bolus | GH secretory capacity testing, receptor pharmacology |
| Short-cycle | 2× daily × 7–14 days | Short-term GH pulse studies, desensitization kinetics |
| Maintenance (with cycle breaks) | Once daily × 5 days on, 2 days off | Sustained GH studies with partial receptor recovery |
| Cardiac research | Variable timing relative to ischemic event | Cardioprotective mechanism studies |
Important: Most long-term hexarelin research protocols incorporate mandatory cycle breaks (typically 2 days off per week, or 2 weeks on / 2 weeks off) specifically to manage desensitization.
---
Reconstitution Protocol for Research Use
> For research purposes only. The following reconstitution instructions are provided for laboratory researchers handling lyophilized hexarelin peptide.
Materials Required
- •Lyophilized hexarelin powder (verified purity ≥98% by HPLC)
- •Bacteriostatic water (0.9% benzyl alcohol in sterile water) — preferred for multi-dose vials
- •Sterile water for injection (for single-use reconstitution)
- •Insulin syringe (0.3 mL, 29–31 gauge recommended)
- •Alcohol swabs
- •Cold storage (2–8°C refrigerator)
Standard Reconstitution Steps
Example: Reconstituting a 2 mg (2,000 mcg) vial for 100 mcg/mL concentration:
1. Wipe the rubber stopper of both the hexarelin vial and the bacteriostatic water vial with an alcohol swab; allow to dry
2. Draw 2.0 mL of bacteriostatic water into the syringe
3. Inject the bacteriostatic water slowly along the inner wall of the hexarelin vial — do not inject directly onto the lyophilized powder cake
4. Gently swirl (do not shake) the vial until the powder is fully dissolved; the solution should be clear and colorless
5. Label with reconstitution date and concentration
6. Each 0.1 mL (10 units on an insulin syringe) = 100 mcg hexarelin at this concentration
Alternative concentration (2 mg vial + 1 mL water = 200 mcg/mL): Each 0.05 mL (5 units) = 100 mcg
Reconstitution Reference Table
| Vial Size | Bacteriostatic Water | Resulting Concentration | 100 mcg Dose Volume |
|---|---|---|---|
| 2 mg | 1.0 mL | 2,000 mcg/mL | 0.05 mL (5 IU) |
| 2 mg | 2.0 mL | 1,000 mcg/mL | 0.10 mL (10 IU) |
| 5 mg | 2.5 mL | 2,000 mcg/mL | 0.05 mL (5 IU) |
| 5 mg | 5.0 mL | 1,000 mcg/mL | 0.10 mL (10 IU) |
Storage After Reconstitution
- •Refrigerate at 2–8°C immediately after reconstitution
- •Reconstituted hexarelin with bacteriostatic water: stable up to 30 days refrigerated
- •Unconstituted lyophilized powder: stable 2+ years at -20°C; 6–12 months at 2–8°C
- •Protect from light; avoid repeated freeze-thaw cycles
---
Timing Strategies in Research Protocols
Fasted State Administration
Hexarelin — like all GHRPs — produces significantly higher GH pulses when administered in a fasted state. Research consistently shows that:
- •Somatostatin tone (which blunts GH secretion) is lower during fasting
- •Insulin and glucose levels are lower, reducing negative GH feedback
- •The GH AUC from hexarelin in a fasted state is typically 40–60% higher than post-prandially
Most published human studies administered hexarelin after a minimum 8-hour overnight fast.
Timing Relative to Sleep
GH secretion follows a strong circadian pattern, with the largest natural GH pulse occurring during early slow-wave sleep. Research has explored hexarelin administration:
- •Pre-sleep (30–60 min before bed): Amplifies the natural sleep-associated GH pulse; used in pituitary reserve testing
- •Morning fasted: Used when cortisol co-release is a confounding factor to be controlled
- •Multiple-daily: Studies using 2–3× daily dosing administered doses ~6–8 hours apart to minimize receptor overlap
Injection Route
All published clinical hexarelin studies used subcutaneous (SC) injection. Intravenous (IV) routes have also been studied (primarily in receptor pharmacology work) and show faster onset but shorter duration. Intramuscular (IM) administration is not commonly reported in the literature.
---
Desensitization: The Critical Hexarelin Research Consideration
Hexarelin desensitization is the most important pharmacological feature distinguishing it from other GHRPs. Published data show:
Desensitization Timeline
- •Acute (hours): Minimal receptor downregulation after single doses; repeated injections within the same day show ~20% GH attenuation in the second pulse
- •Short-term (days 1–7): GH response is largely maintained with once-daily dosing; minor (~15–25%) decline observed by day 7
- •Intermediate (weeks 2–4): GH response declines to 40–60% of baseline peak with continuous daily dosing — the primary desensitization window
- •Prolonged (>4 weeks): Continued blunting to 30–50% of initial response; recovery begins within 72 hours of cessation
A landmark study by Ghigo et al. (1994) demonstrated that 16 weeks of twice-daily hexarelin produced sustained GH responses in GH-deficient children, but with progressive peak blunting — suggesting partial tolerance, not complete desensitization.
Managing Desensitization in Research Protocols
Strategies used in published research to manage desensitization:
1. Cyclic protocols: 2 weeks on / 2 weeks off; receptor sensitivity largely recovers within 14 days of cessation
2. 5-on/2-off weekly schedule: Partial recovery over weekends; practical for longer research windows
3. Dose rotation with GHRH analogs: Alternating hexarelin with a GHRH peptide (Sermorelin, CJC-1295) reduces GHSR-1a receptor burden while maintaining GH stimulation via different receptor populations
4. Reduced frequency: Dropping to every-other-day dosing after initial response characterization reduces cumulative receptor load
---
Cardioprotective Effects: A Distinct Research Domain
Hexarelin's cardiovascular research applications are mechanistically separate from its GH-releasing properties and represent an active area of independent research.
Key Cardioprotective Findings
Ischemia-Reperfusion Protection:
- •Mao et al. (2007): Hexarelin pretreatment reduced infarct size by 38% in a rat ischemia-reperfusion model; effect persisted in GH-deficient rats, confirming GH-independent mechanism
- •The protection was associated with increased Bcl-2/Bax ratio (anti-apoptotic) and activation of ERK1/2 survival signaling
Heart Failure Models:
- •Xu et al. (2010): Chronic hexarelin treatment improved left ventricular ejection fraction (LVEF) and reduced cardiac fibrosis in heart failure models, mediated through CD36-dependent pathways
Anti-Inflammatory Cardiac Effects:
- •Hexarelin attenuates NF-κB signaling in cardiac tissue, reducing pro-inflammatory cytokine expression (TNF-α, IL-6) during ischemic stress
Research Doses Used in Cardiac Studies
Cardiac research has used substantially different dosing approaches than GH stimulation studies:
- •Acute cardioprotection: Single IV bolus of 80–100 mcg/kg body weight, administered pre-ischemia in animal models
- •Chronic cardiac remodeling studies: 100 mcg/kg SC, daily × 4 weeks in heart failure models
These doses are substantially higher on a per-kg basis than standard GH stimulation doses in human research, and reflect the different receptor affinity thresholds for CD36 versus GHSR-1a activation.
---
Combination Protocols in GH Research
Hexarelin + GHRH Analogs (Synergistic Stack)
Combining hexarelin with a GHRH peptide is the most studied combination approach. The synergy is mechanistic:
- •GHRH increases GHSR-1a expression on somatotrophs (sensitizing cells to hexarelin)
- •Hexarelin amplifies GHRH-stimulated GH release 3–5× beyond additive effects
- •The combination avoids somatostatin-mediated blunting more effectively than either peptide alone
Published combination approaches:
- •Hexarelin (1 mcg/kg) + GHRH (1 mcg/kg): Used in standard pituitary reserve testing
- •Lower hexarelin doses (0.5 mcg/kg) with CJC-1295 (no-DAC): Reduces cortisol/prolactin co-release while maintaining GH synergy
Avoiding IGF-1/Insulin Co-administration
Research protocols generally avoid co-administration of hexarelin with IGF-1 or insulin, as these agents suppress somatotroph sensitivity through independent negative feedback pathways, confounding GH response measurements.
---
Safety Profile in Research: Reported Effects
The following effects have been observed in published human and animal studies with hexarelin:
Commonly Reported (Human Studies):
- •Mild transient facial flushing (related to GH vasodilation)
- •Increased appetite (moderate; less than GHRP-6)
- •Mild water retention at higher doses (GH-related)
- •Cortisol elevation (15–45% above baseline in most studies; returns to baseline within 2–4 hours)
- •Prolactin elevation (transient; typically resolves within 2–3 hours)
Observed in Animal Studies at High Doses:
- •Adrenal cortex stimulation with chronic high-dose (>3 mcg/kg) protocols
- •Hypophyseal cell changes with very long-duration studies (>20 weeks)
Not observed in published studies: Significant hepatotoxicity, nephrotoxicity, or reproductive organ changes at standard research doses.
These findings are reported from controlled research settings and do not represent a safety endorsement for human use outside an approved clinical trial context.
---
Summary: Key Research Parameters at a Glance
| Parameter | Research Range | Notes |
|---|---|---|
| Dose (SC injection) | 1–2 mcg/kg (≈ 75–150 mcg for 75 kg) | Saturation plateau above 2 mcg/kg |
| Frequency | Once to twice daily | 2× daily shows faster desensitization |
| Administration route | Subcutaneous (most common) | IV used in receptor pharmacology work |
| Fasting recommended | Yes (8+ hours) for maximal GH response | Fed-state blunts GH AUC by 40–60% |
| Reconstitution | Bacteriostatic water | 2 mg vial + 2 mL = 1,000 mcg/mL |
| Post-reconstitution stability | ~30 days at 2–8°C | Protect from light |
| Desensitization onset | Week 2–4 with daily dosing | Use cyclic protocols (2 on / 2 off) |
| Cycle length | 2–4 weeks on, ≥2 weeks off | Sensitivity largely recovers in 14 days |
---
Frequently Asked Questions
How does hexarelin compare to GHRP-2 for GH stimulation research?
Hexarelin produces larger acute GH pulses — approximately 2–3× higher peak GH — than GHRP-2 at equivalent molar doses. However, hexarelin also produces higher cortisol and prolactin co-release and desensitizes faster. GHRP-2 is often preferred for research requiring sustained repeated dosing with minimal receptor tolerance.
Why does hexarelin cause desensitization faster than other GHRPs?
The higher receptor affinity and intrinsic efficacy that makes hexarelin the most potent GHRP also drives faster receptor internalization and downregulation. High-affinity agonists typically produce more rapid receptor desensitization — a well-established pharmacological principle observed across multiple receptor systems.
Can hexarelin's cardioprotective effects be separated from its GH-releasing activity?
Research in GH-deficient and hypophysectomized animal models confirms that hexarelin's cardiac effects (reduced infarct size, improved ventricular function) persist even when pituitary GH secretion is absent. This confirms the cardioprotective mechanism operates through CD36 and cardiovascular GHSR isoforms independently of the hypothalamic-pituitary axis.
What is the recovery time after hexarelin desensitization?
Based on published data, GHSR-1a sensitivity largely recovers within 14 days of hexarelin cessation. Some studies have demonstrated measurable partial recovery as early as 72 hours. Extended protocols (>8 weeks) may require longer recovery periods.
---
Related Research Resources
For researchers studying hexarelin within the broader context of GHRP pharmacology:
- •See GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin for a comprehensive receptor-level comparison of all four major GHRPs
- •See Hexarelin: The Most Potent GHRP — Complete Research Profile for full pharmacokinetic and mechanism data
---
Key References
1. Arvat E, et al. "Hexarelin, a synthetic GH-releasing peptide, is a potent activator of the hypothalamo-pituitary GH axis in humans." Acta Endocrinologica (Copenh). 1994;130(3):216–223.
2. Ghigo E, et al. "Growth hormone (GH)-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man." Journal of Clinical Endocrinology & Metabolism. 1994;78(3):693–698.
3. Arvat E, et al. "Hexarelin versus GHRP-6: a comparison of their neuroendocrine activities in man." Growth Hormone & IGF Research. 1997;7(6):397–402.
4. Mao Y, et al. "Hexarelin protects cardiomyocytes against ischemia/reperfusion injury through activation of PI3K/Akt and ERK1/2 signaling." American Journal of Physiology — Heart and Circulatory Physiology. 2007;292(2):H925–H933.
5. Broglio F, et al. "Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans." Journal of Clinical Endocrinology & Metabolism. 2003;88(4):1413–1417.
6. Xu X, et al. "Hexarelin improves cardiac function and attenuates cardiac remodeling in a rat model of coronary artery ligation-induced heart failure." American Journal of Translational Research. 2010;2(3):310–318.
---
> Research Use Only: This article is intended for researchers and educators. Hexarelin has not been approved by the FDA or any other regulatory agency for human therapeutic use. The dosing information presented here is derived from published scientific literature and does not constitute medical advice, clinical guidance, or a recommendation for human administration. Researchers handling hexarelin should follow all applicable institutional biosafety protocols and regulatory requirements.